Boston Scientific Corporation (BSX) P/E Ratio History
Deep ValueTrading at 23.3x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 1992–2025
Loading P/E history...
P/E Ratio Analysis
As of June 21, 2026, Boston Scientific Corporation (BSX) trades at a price-to-earnings ratio of 23.3x, with a stock price of $45.29 and trailing twelve-month earnings per share of $1.93.
The current P/E is 74% below its 5-year average of 89.4x. Over the past five years, BSX's P/E has ranged from a low of 49.4x to a high of 395.2x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, BSX is roughly in line with its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, BSX trades roughly in line with the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BSX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BSX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
BSX P/E vs Peers
Cardiovascular and heart rhythm devices peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $102B | 22.0 | - | +31% | |
| $50B | 47.7 | 6.74 | -74% | |
| $118B | 36.6 | 2.46 | +8% | |
| $17B | 24.8 | - | -20% | |
| $52B | 24.7 | 1.49 | -1% | |
| $17B | 30.5 | - | -25% | |
| $154B | 11.6Lowest | 0.39Best | +134%Best | |
| $144B | 51.7 | 2.37 | +23% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
BSX Historical P/E Data (1992–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Dec 31 2025 | $95.35 | $1.93 | 49.4x | -42% |
| FY2025 Q3 | - | $97.63 | $1.86 | 52.5x | -38% |
| FY2025 Q2 | Jun 30 2025 | $107.41 | $1.68 | 64.1x | -25% |
| FY2025 Q1 | Mar 31 2025 | $100.88 | $1.36 | 73.9x | -13% |
| FY2024 Q4 | - | $89.32 | $1.25 | 71.6x | -16% |
| FY2024 Q3 | Sep 30 2024 | $83.80 | $1.21 | 69.3x | -18% |
| FY2024 Q2 | Jun 30 2024 | $77.01 | $1.24 | 62.3x | -27% |
| FY2024 Q1 | Mar 31 2024 | $68.49 | $1.20 | 57.2x | -33% |
| FY2023 Q4 | Dec 31 2023 | $57.81 | $1.07 | 54.0x | -36% |
| FY2023 Q3 | Sep 30 2023 | $52.80 | $0.82 | 64.7x | -24% |
| FY2023 Q2 | Jun 30 2023 | $54.09 | $0.59 | 90.9x | +7% |
| FY2023 Q1 | Mar 31 2023 | $50.03 | $0.59 | 85.3x | +0% |
| FY2022 Q4 | Dec 31 2022 | $46.27 | $0.45 | 103.6x | +22% |
| FY2022 Q3 | Sep 30 2022 | $38.73 | $0.41 | 93.3x | +10% |
| FY2022 Q2 | - | $37.27 | $0.58 | 64.7x | -24% |
| FY2022 Q1 | - | $44.29 | $0.53 | 84.3x | -1% |
| FY2021 Q4 | Dec 31 2021 | $42.48 | $0.69 | 61.9x | -27% |
| FY2021 Q3 | - | $43.39 | $0.73 | 59.7x | -30% |
| FY2021 Q2 | Jun 30 2021 | $42.76 | $0.33 | 131.0x | +54% |
| FY2021 Q1 | Mar 31 2021 | $38.65 | $0.10 | 395.2x | +365% |
| FY2020 Q3 | Sep 30 2020 | $38.21 | $2.61 | 14.6x | -83% |
| FY2020 Q2 | - | $35.11 | $2.82 | 12.5x | -85% |
| FY2020 Q1 | - | $32.63 | $3.03 | 10.8x | -87% |
| FY2019 Q4 | - | $45.22 | $3.33 | 13.6x | -84% |
| FY2019 Q3 | Sep 30 2019 | $40.69 | $0.77 | 52.9x | -38% |
| FY2019 Q2 | Jun 30 2019 | $42.98 | $0.99 | 43.4x | -49% |
| FY2019 Q1 | Mar 31 2019 | $38.38 | $1.28 | 30.0x | -65% |
| FY2018 Q4 | Dec 31 2018 | $35.34 | $1.19 | 29.7x | -65% |
| FY2018 Q3 | Sep 30 2018 | $38.50 | $0.47 | 81.9x | -4% |
| FY2018 Q2 | Jun 30 2018 | $32.70 | $0.36 | 90.8x | +7% |
| FY2018 Q1 | Mar 31 2018 | $27.32 | $0.07 | 420.3x | +395% |
| FY2017 Q4 | Dec 31 2017 | $24.79 | $0.07 | 381.4x | +349% |
| FY2017 Q3 | Sep 30 2017 | $29.17 | $0.60 | 48.2x | -43% |
| FY2017 Q2 | Jun 30 2017 | $27.72 | $0.57 | 48.2x | -43% |
| FY2017 Q1 | Mar 31 2017 | $24.87 | $0.32 | 77.7x | -9% |
| FY2016 Q4 | Dec 31 2016 | $21.63 | $0.26 | 83.2x | -2% |
| FY2016 Q3 | Sep 30 2016 | $23.80 | $0.06 | 396.7x | +367% |
| FY2015 Q2 | - | $17.70 | $0.17 | 103.8x | +22% |
| FY2015 Q1 | - | $17.75 | $0.10 | 180.0x | +112% |
| FY2014 Q4 | Dec 31 2014 | $13.25 | $0.20 | 67.0x | -21% |
| FY2014 Q3 | - | $11.81 | $0.21 | 55.4x | -35% |
| FY2014 Q2 | Jun 30 2014 | $12.77 | $0.18 | 71.9x | -15% |
| FY2014 Q1 | Mar 31 2014 | $13.52 | $0.27 | 50.0x | -41% |
| FY2012 Q1 | Mar 31 2012 | $5.98 | $0.34 | 17.6x | -79% |
| FY2011 Q4 | Dec 31 2011 | $5.34 | $0.27 | 19.4x | -77% |
| FY2011 Q3 | Sep 30 2011 | $5.91 | $0.35 | 16.8x | -80% |
| FY2011 Q2 | - | $6.91 | $0.38 | 18.3x | -78% |
| FY2011 Q1 | - | $7.19 | $0.35 | 20.7x | -76% |
| FY2007 Q3 | Sep 30 2007 | $13.95 | $0.16 | 89.0x | +5% |
| FY2007 Q2 | Jun 30 2007 | $15.34 | $0.39 | 39.7x | -53% |
| FY2006 Q1 | Mar 31 2006 | $23.05 | $0.71 | 32.5x | -62% |
| FY2005 Q4 | Dec 31 2005 | $24.49 | $0.73 | 33.5x | -61% |
| FY2005 Q3 | Sep 30 2005 | $23.37 | $0.68 | 34.4x | -60% |
| FY2005 Q2 | - | $27.00 | $1.31 | 20.6x | -76% |
| FY2005 Q1 | - | $29.29 | $1.43 | 20.5x | -76% |
| FY2004 Q4 | Dec 31 2004 | $35.55 | $1.24 | 28.7x | -66% |
| FY2004 Q3 | - | $39.73 | $1.05 | 37.8x | -55% |
| FY2004 Q2 | Jun 30 2004 | $42.80 | $0.90 | 47.6x | -44% |
| FY2004 Q1 | Mar 31 2004 | $42.38 | $0.68 | 62.3x | -27% |
| FY2003 Q4 | Dec 31 2003 | $36.76 | $0.56 | 65.6x | -23% |
| FY2003 Q3 | - | $31.90 | $0.52 | 61.3x | -28% |
| FY2003 Q2 | Jun 30 2003 | $30.55 | $0.56 | 54.6x | -36% |
| FY2003 Q1 | Mar 31 2003 | $20.38 | $0.45 | 45.3x | -47% |
| FY2002 Q4 | - | $21.26 | $0.44 | 48.3x | -43% |
| FY2002 Q3 | Sep 30 2002 | $15.78 | $0.40 | 39.5x | -53% |
| FY2002 Q2 | Jun 30 2002 | $14.66 | $0.28 | 52.5x | -38% |
| FY2002 Q1 | Mar 31 2002 | $12.54 | $0.04 | 319.2x | +276% |
| FY2001 Q1 | Mar 31 2001 | $10.09 | $0.30 | 33.1x | -61% |
| FY2000 Q4 | Dec 31 2000 | $6.84 | $0.44 | 15.6x | -82% |
| FY2000 Q3 | Sep 30 2000 | $8.22 | $0.51 | 16.1x | -81% |
| FY2000 Q2 | Jun 30 2000 | $10.97 | $0.47 | 23.1x | -73% |
| FY2000 Q1 | Mar 31 2000 | $10.66 | $0.46 | 23.4x | -72% |
| FY1999 Q4 | Dec 31 1999 | $10.94 | $0.46 | 24.0x | -72% |
| FY1999 Q3 | - | $12.38 | $0.45 | 27.8x | -67% |
| FY1998 Q2 | - | $17.91 | $0.32 | 56.6x | -33% |
| FY1998 Q1 | - | $16.88 | $0.16 | 104.4x | +23% |
| FY1997 Q4 | Dec 31 1997 | $11.47 | $0.17 | 67.7x | -20% |
| FY1997 Q3 | - | $13.80 | $0.27 | 51.8x | -39% |
| FY1997 Q2 | Jun 30 1997 | $15.36 | $0.24 | 63.4x | -25% |
| FY1997 Q1 | Mar 31 1997 | $15.44 | $0.31 | 49.7x | -41% |
| FY1996 Q4 | - | $15.00 | $0.22 | 69.0x | -19% |
| FY1996 Q3 | Sep 30 1996 | $14.38 | $0.09 | 152.0x | +79% |
| FY1996 Q2 | Jun 30 1996 | $11.25 | $0.09 | 126.5x | +49% |
| FY1996 Q1 | Mar 31 1996 | $11.50 | $0.13 | 88.0x | +4% |
| FY1995 Q4 | Dec 31 1995 | $12.31 | $0.01 | 1017.6x | +1098% |
| FY1995 Q3 | Sep 30 1995 | $10.88 | $0.07 | 147.6x | +74% |
| FY1995 Q2 | Jun 30 1995 | $7.97 | $0.04 | 182.4x | +115% |
| FY1995 Q1 | Mar 31 1995 | $6.16 | $0.02 | 329.2x | +288% |
| FY1994 Q4 | Dec 31 1994 | $4.34 | $0.18 | 23.6x | -72% |
| FY1994 Q3 | Sep 30 1994 | $3.97 | $0.20 | 20.3x | -76% |
| FY1994 Q2 | - | $3.16 | $0.19 | 16.5x | -81% |
| FY1994 Q1 | - | $3.38 | $0.19 | 18.2x | -79% |
| FY1993 Q4 | Dec 31 1993 | $3.13 | $0.18 | 17.3x | -80% |
| FY1993 Q3 | - | $2.56 | $0.17 | 15.0x | -82% |
| FY1993 Q2 | Jun 30 1993 | $3.50 | $0.17 | 21.1x | -75% |
| FY1993 Q1 | Mar 31 1993 | $4.00 | $0.16 | 25.7x | -70% |
| FY1992 Q4 | - | $5.22 | $0.15 | 34.6x | -59% |
Average P/E for displayed period: 84.9x
Full Stock Analysis
Deep dive into BSX consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
34+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BSX — Frequently Asked Questions
Quick answers to the most common questions about buying BSX stock.
What is BSX's P/E ratio?
Boston Scientific Corporation (BSX) trailing twelve-month P/E ratio is 23.3x, based on TTM diluted EPS of $1.93. The 5-year average P/E is 89.4x and the historical range spans 49.4x to 395.2x.
Is BSX stock overvalued or undervalued?
BSX trades at 23.3x P/E, below its 5-year average of 89.4x. At the 0th percentile of its historical range (49.4x–395.2x), the stock is priced at a discount to its own history.
Is BSX stock expensive?
No, BSX is not expensive on a historical basis. The current P/E of 23.3x is below the 5-year average of 89.4x and sits at the 0th percentile of its valuation range.
What is BSX's historical P/E range?
Over the past 5 years, BSX's P/E ratio has ranged from 49.4x to 395.2x, with a median of 69.3x and an average of 89.4x. The current P/E of 23.3x places the stock at the 0th percentile of this range. Full historical data spans 1992–2025.
How does BSX's P/E compare to the S&P 500?
BSX trades at 23.3x P/E versus the S&P 500 median of 24.4x. The 5% discount to the market suggests lower growth expectations or perceived higher risk.
How does BSX's valuation compare to Healthcare peers?
Boston Scientific Corporation P/E of 23.3x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is BSX's PEG ratio?
BSX PEG ratio is N/A, based on a P/E of 23.3x and EPS growth of 55.2%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is BSX's earnings yield?
BSX earnings yield is 4.28%, the inverse of its 23.3x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.